The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

BACKGROUND: Targeted therapies have improved survival and quality of life for patients with non-small-cell lung cancer with actionable driver mutations. However, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 gene (HER2, also known as ERBB2) exon 20 insertions (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirchner, M., Kluck, K., Brandt, R., Volckmar, A.-L., Penzel, R., Kazdal, D., Endris, V., Neumann, O., Seker-Cin, H., Goldschmid, H., Glade, J., Allgäuer, M., Kriegsmann, M., Winter, H., Muley, T., Perner, S., Frost, N., Reck, M., Fröhling, S., Schirmacher, P., Thomas, M., Budczies, J., Christopoulos, P., Stenzinger, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426209/
https://www.ncbi.nlm.nih.gov/pubmed/34487971
http://dx.doi.org/10.1016/j.esmoop.2021.100253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426209/
https://www.ncbi.nlm.nih.gov/pubmed/34487971
http://dx.doi.org/10.1016/j.esmoop.2021.100253

Ejemplares similares